Empowering women to live healthier lives!
Call Us! 800-994-9662
Monday–Friday 9 a.m.–6 p.m. (EST)
Text size
Email
Print
Abraxane Approved to Treat Advanced Lung Cancer
FRIDAY, Oct. 12 (HealthDay News) -- Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration -- in combination with the drug carboplatin -- to treat advanced or spreading non-small cell lung cancer among people who aren't candidates for surgery or radiation therapy, the agency said Friday.
Abraxane was first approved in 2005 to treat breast cancer.
In a new clinical study of 1038 people, the most common adverse reactions to the drug were anemia, loss of hair, nausea, fatigue, loss of appetite, irregularity, rash and swelling.
Abraxane is produced by Celgene Corp., based in Summit, N.J.
More information
To learn more about non-small cell lung cancer, visit the U.S. National Cancer Institute.
Copyright © 2012 HealthDay. All rights reserved.
HealthDay news articles are derived from various sources and do not reflect federal policy. Womenshealth.gov does not endorse opinions, products, or services that may appear in news stories.
A federal government website managed by the Office on Women's Health in the Office of the Assistant Secretary for Health at the U.S. Department of Health and Human Services.200 Independence Avenue, S.W. • Washington, DC 20201
202-690-7650 • Monday through Friday, 9 a.m. to 5 p.m. EST (closed on federal holidays).
womenshealth.gov
A federal government website managed by the Office on Women's Health in the Office of the Assistant Secretary for Health at the U.S. Department of Health and Human Services.
200 Independence Avenue, S.W. • Washington, DC 20201